BlackRock, Inc.NYSE: BLK

Major shareholder announcement - BlackRock, Inc.

· Issued by BlackRock, Inc. via GlobeNewswire

Summary by 6ix AI

BlackRock, Inc. notified ChemoMetec A/S that on November 6, 2026 it increased its voting rights attached to shares in ChemoMetec A/S to 15.02%, exceeding the 15% threshold under section 38 of the Danish Capital Markets Act. ChemoMetec makes instruments for cell counting and other measurements.

Key details

  • At that time BlackRock, Inc. also held 0.22% of voting rights through financial instruments, for a total of 15.24%.
  • The notice was given under section 30 of the Danish Capital Markets Act.

6ix AI wrote this summary from the release below and checked it against the release.

ANNOUNCEMENT NO. 328
11 November 2026

Pursuant to section 30 of the Danish Capital Markets Act, notice is hereby given that BlackRock, Inc. has notified ChemoMetec A/S that, on 6 November 2026, BlackRock, Inc. increased its voting rights attached to shares in ChemoMetec A/S to 15.02%, thereby exceeding the 15% threshold pursuant to section 38 of the Danish Capital Markets Act.

BlackRock, Inc.’s position at that time was as follows:

  • Voting rights attached to shares: 15.02%
  • Voting rights through financial instruments: 0.22%
  • The total of both: 15.24%

Additional Information
Martin Helbo Behrens, CEO
Tel.: (+45) 81 10 06 80

Phillip Massie Price, CFO
Tel.: (+45) 81 10 06 80

About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.

Attachment

View original source (GlobeNewswire)BlackRock, Inc. on 6ix

Earlier from BlackRock

Later from BlackRock

All BlackRock news releases